ACAD

ACADIA Pharmaceuticals Inc. | Cotação de Ações

Última atualização21/04/2025, 11:23:49

PreçoUS$ 14,56

Variação (dia)-US$ 0,17 (-1.15%)▼

Min. 52 SemanasUS$ 13,40

Máx. 52 SemanasUS$ 20,68

Capitalização de mercado--

Endereço: 12830 El Camino Real, San Diego, CA, 92130

Telefone: 858 558 2871

Funcionários: 653

ACADIA Pharmaceuticals Inc.ACAD

US$ 14,56

- 0,171,2%

21/04/2025 11:23:49

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 14,56

Valor de mercado--

AberturaUS$ 14,70

Preço máximoUS$ 14,60

Preço mínimoUS$ 14,35

VolumeUS$ 128 mil

Fechamento anteriorUS$ 14,73

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ações relacionadas

Sarepta Therapeutics, Inc.

SRPT ▲0.50% | US$ 117,39

Alnylam Pharmaceuticals, Inc.

ALNY ▲4.68% | US$ 281,41

BioMarin Pharmaceutical Inc.

BMRN ▲1.32% | US$ 63,12

Amicus Therapeutics, Inc.

FOLD ▲0.06% | US$ 9,74

Celldex Therapeutics, Inc.

CLDX ▼0.07% | US$ 24,47

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.